Martin Mackay insider trades
Open-market stock purchases and sales by Martin Mackay, Director at Charles River Laboratories International, Inc, from SEC Form 4 filings since Dec 31, 2009.
Track record: 100% of 2 scored buys are up 5% or more since purchase, averaging +53%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 8, 2026 | CRL Charles River Laboratories International, Inc | Bought (not open market) | $255K |
| May 8, 2026 | CRL Charles River Laboratories International, Inc | Bought (not open market) | $250K |
| Apr 16, 2026 | KLRA Kailera Therapeutics, Inc | Bought (not open market) | — |
| Feb 18, 2026 | RLYB Rallybio Corp | Bought (not open market) | $65K |
Companies traded
- CRL Charles River Laboratories International, Inc: other filings, last May 8, 2026
- KLRA Kailera Therapeutics, Inc: other filings, last Apr 16, 2026
- RLYB Rallybio Corp: 2 buys, last Feb 18, 2026
- SWTX SpringWorks Therapeutics, Inc: other filings, last Jul 1, 2025
- FVAM 5:01 Acquisition Corp: other filings, last Oct 16, 2020
- ALXN Alexion Pharmaceuticals Inc: 27 sales, last Mar 1, 2017
- PFE Pfizer Inc: other filings, last May 14, 2010